Welcome to our dedicated page for Cronos Group news (Ticker: CRON), a resource for investors and traders seeking the latest updates and insights on Cronos Group stock.
Cronos Group Inc. reports developments for a global cannabis and cannabinoid company focused on consumer goods, cannabis research, technology and product development. Its brand portfolio includes Spinach®, PEACE NATURALS®, LIT® and Lord Jones®, with news often centered on product innovation across Canadian cannabis formats such as pre-rolls and vapes.
Recurring Cronos updates also cover operating and financial results, earnings conference calls, annual shareholder meetings, proxy and governance matters, capital-structure disclosures and public-company presentations. The company’s disclosures connect brand launches and R&D-driven product development with the financial and governance reporting of a Nasdaq- and TSX-listed cannabis issuer.
Cronos Group (NASDAQ: CRON) has released a Sustainability Study in honor of Earth Day, highlighting the environmental benefits of its innovative fermentation manufacturing methods for cannabinoid production compared to traditional indoor cultivation methods. The study reveals that using Cronos’ fermentation techniques results in an average carbon footprint savings of 99.8% compared to conventional extraction methods, significantly reducing environmental harm across various metrics. The company’s Spinach FEELZ™ brand features products made using these sustainable methods, focusing on rare cannabinoids like CBC and CBG. Cronos aims to lead the cannabis industry towards more sustainable practices, reinforcing the importance of adopting such innovative technologies for future growth.
Cronos Group Inc. (NASDAQ: CRON) announced an expansion of its Spinach® brand with new infused pre-roll offerings, reflecting a significant growth in market share. The Spinach® infused pre-rolls gained 2.5% market share in Q1 2023, rising to 8th place from 16th in Q4 2022. The Canadian cannabis pre-roll market grew by 38% year-over-year, with infused pre-rolls comprising approximately 24% of that share. Notable products include Spinach® Fully Charged Atomic GMO with 35% Total THC and various flavor profiles aiming to enhance consumer experience. Cronos emphasizes innovation and consumer engagement, anticipating continued growth through their new product launches.
Cronos Group Inc. reported a 23% increase in consolidated net revenue for Full Year 2022, reaching $91.9 million, compared to $74.4 million in 2021. The company's net revenue in Israel surged 128%, significantly boosting overall performance. In Q4 2022, net revenue was $22.9 million, a decline of 11% year-over-year due to lower sales in the U.S. The company ended 2022 with $878 million in cash and short-term investments. Notably, Spinach® became the top edible brand in Canada as of January 2023. The CEO emphasized cost-saving measures yielding $28.7 million savings in 2022, with an additional anticipated savings of $10-20 million in 2023.
Cronos Group Inc. (NASDAQ: CRON) has announced its conference call for the 2022 fourth quarter and full-year earnings on February 28, 2023, at 8:30 a.m. ET. The call aims to provide insights into the Company’s financial results and allow for questions from the investment community. Participants can register for the call online to ensure timely access. The company is committed to advancing cannabis research and product development across its international brand portfolio, which includes Spinach®, PEACE NATURALS®, and Lord Jones®.
Cronos Group Inc. has announced that its Spinach® gummies have achieved the status of the top-selling edible brand in Canada, commanding a 15.8% market share of the total edibles category as of January 2023. Launched in 2021, Spinach® includes SOURZ by Spinach™ and Spinach FEELZ™, both recognized for their unique flavors and proprietary technology. Cronos expects this success to bolster its market presence and support future product innovations. This achievement is seen as a validation of Cronos' innovation and marketing strategies as it aims to expand its product lineup globally.
Cronos Group Inc. announced the voluntary relinquishment of a warrant by Altria Group's subsidiary, Altria Summit LLC, allowing the purchase of up to 84,243,223 common shares at C$19.00 per share. This decision was made on December 16, 2022, without any financial consideration. Despite this, Altria retains ownership of 156,573,537 common shares and four board designees, ensuring continued influence. The relinquishment does not alter Altria's rights under the Investor Rights Agreement established in 2019.
Cronos Group has launched its innovative Spinach FEELZ™ THC+CBC Day Trip Mango Lime gummies, marking the first CBC gummy product in Canada.
Featuring a unique 3:1 ratio of CBC to THC, these gummies are available in Alberta and British Columbia, with plans for wider distribution.
The product contains 10mg of THC and 30mg of CBC per pack, targeting adults seeking enhanced experiences. Cronos is set to issue approximately 489,000 common shares to Ginkgo Bioworks for the commercialization of CBC, reflecting a strategic partnership for cannabinoid development.
Cronos Group, a leading global cannabinoid company, will have its CEO, Mike Gorenstein, speaking at the Stifel Canada’s 3rd Annual Future of Healthcare Conference on December 7, 2022, at 1:00 p.m. ET. The event will be available via webcast on Cronos' Investor website. The company is focused on innovative cannabis research and technology, developing an iconic brand portfolio that includes Spinach®, PEACE NATURALS®, Lord Jones®, Happy Dance®, and PEACE+®. For more information, visit thecronosgroup.com.
Cronos Group Inc. (NASDAQ: CRON) announced the appointment of James Holm as Chief Financial Officer, effective immediately, succeeding Bob Madore. Holm has nearly two decades of experience in finance, having previously worked at Vertiv, Worldpay, and Procter & Gamble. CEO Mike Gorenstein emphasized Holm's strategic thinking and financial expertise, which are expected to enhance Cronos' margin expansion and revenue growth strategies. Holm expressed enthusiasm for joining Cronos and contributing to the company's growth initiatives, signaling a potential positive shift in financial leadership.
Cronos Group announced its Q3 2022 results, with consolidated net revenue rising 3% YoY to $20.9 million, driven by an 88% increase in Israeli revenue. Adjusted EBITDA improved by $25.1 million YoY, indicating operational efficiencies. The company aims for $20-$25 million in operating expense savings for 2022. Notable product successes include SOURZ by Spinach™, a top edible in Canada. However, U.S. revenue fell by 76% to $514, and net income declined significantly. The appointment of Jeff Jacobson as Chief Growth Officer signals a focus on growth strategies moving forward.